- Home
- LFUS vs ALKS Comparison
LFUS vs ALKS Comparison
Compare LFUS & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFUS
- ALKS
- Stock Information
- Founded
- LFUS 1927
- ALKS 1987
- Country
- LFUS United States
- ALKS Ireland
- Employees
- LFUS N/A
- ALKS N/A
- Industry
- LFUS Electrical Products
- ALKS Biotechnology: Pharmaceutical Preparations
- Sector
- LFUS Energy
- ALKS Health Care
- Exchange
- LFUS Nasdaq
- ALKS Nasdaq
- Market Cap
- LFUS 4.4B
- ALKS 5.1B
- IPO Year
- LFUS N/A
- ALKS 1991
- Fundamental
- Price
- LFUS $219.17
- ALKS $29.09
- Analyst Decision
- LFUS Buy
- ALKS Buy
- Analyst Count
- LFUS 5
- ALKS 12
- Target Price
- LFUS $252.25
- ALKS $40.00
- AVG Volume (30 Days)
- LFUS 166.3K
- ALKS 1.6M
- Earning Date
- LFUS 07-29-2025
- ALKS 07-23-2025
- Dividend Yield
- LFUS 1.29%
- ALKS N/A
- EPS Growth
- LFUS N/A
- ALKS N/A
- EPS
- LFUS 3.81
- ALKS 2.09
- Revenue
- LFUS $2,209,690,000.00
- ALKS $1,513,770,000.00
- Revenue This Year
- LFUS $6.40
- ALKS N/A
- Revenue Next Year
- LFUS $7.76
- ALKS $4.25
- P/E Ratio
- LFUS $57.05
- ALKS $13.92
- Revenue Growth
- LFUS N/A
- ALKS N/A
- 52 Week Low
- LFUS $142.10
- ALKS $22.90
- 52 Week High
- LFUS $275.58
- ALKS $36.45
- Technical
- Relative Strength Index (RSI)
- LFUS 55.76
- ALKS 38.82
- Support Level
- LFUS $215.16
- ALKS $29.26
- Resistance Level
- LFUS $222.13
- ALKS $30.52
- Average True Range (ATR)
- LFUS 6.07
- ALKS 0.78
- MACD
- LFUS -0.82
- ALKS -0.24
- Stochastic Oscillator
- LFUS 64.49
- ALKS 4.96
About LFUS Littelfuse Inc.
Littelfuse is a primary provider of circuit protection products (such as fuses and relays) into the transportation, industrial, telecommunications, and consumer electronics end markets. The firm is also increasing its power semiconductor business, where it predominantly serves industrial end markets and is breaking into electric vehicle charging infrastructure. Littelfuse has 17,000 global employees.
About ALKS Alkermes plc
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.